{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:23Z","timestamp":1793600843605,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ophtha.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:41:35Z","timestamp":1771400495000},"page":"886-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor Necrosis Factor-\u03b1 Inhibition and the Unmasking of CNS Demyelination across a Large United States Health Research Network"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2830-9832","authenticated-orcid":false,"given":"Jawad","family":"Muayad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-0152","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-7089","authenticated-orcid":false,"given":"Muhammad Z.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed B.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.02.020_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.02.020_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl Res"},{"issue":"4","key":"10.1016\/j.ophtha.2026.02.020_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1016\/j.ophtha.2026.02.020_bib4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Van Oosten","year":"1996","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ophtha.2026.02.020_bib5","first-page":"422","volume":"1","author":"Mazumdar","year":"2009","journal-title":"Taylor & Francis"},{"key":"10.1016\/j.ophtha.2026.02.020_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ophtha.2024.01.016","article-title":"Association of primary open-angle glaucoma with diabetic retinopathy among patients with type 1 and type 2 diabetes: a large global database study","volume":"131","author":"Chauhan","year":"2024","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2026.02.020_bib7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.020_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2024.02.023","article-title":"Association of ocular manifestations of Marfan syndrome with cardiovascular complications","volume":"264","author":"Tran","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.020_bib9","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ophtha.2026.02.020_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","author":"Lenercept Multiple Sclerosis Study Group","year":"1999","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ophtha.2026.02.020_bib11","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of inflammatory central nervous system diseases after tumor necrosis factor-inhibitor treatment for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.ophtha.2026.02.020_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ophtha.2026.02.020_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2026.02.020_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/acr.25340","article-title":"Risk of neuroinflammatory diseases among new recipients of biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"76","author":"Casey","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.ophtha.2026.02.020_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000909","article-title":"Intermediate uveitis associated with MS: diagnosis, clinical features, pathogenic mechanisms, and recommendations for management","volume":"8","author":"Abraham","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.ophtha.2026.02.020_bib16","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor \u03b1 antagonism: by what mechanisms could tumor necrosis factor \u03b1 antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2026.02.020_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor necrosis factor \u03b1 and regulatory T cells in oncoimmunology","volume":"9","author":"Salomon","year":"2018","journal-title":"Front Immunol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202600120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202600120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:37:09Z","timestamp":1793597829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202600120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S016164202600120X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.020","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Necrosis Factor-\u03b1 Inhibition and the Unmasking of CNS Demyelination across a Large United States Health Research Network","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}